Astria Therapeutics’ (ATXS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Astria Therapeutics (NASDAQ:ATXS) in a report released on Tuesday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock.

A number of other research firms have also issued reports on ATXS. Oppenheimer upped their target price on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Wedbush reiterated an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a report on Tuesday, August 13th. Finally, Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Performance

Astria Therapeutics stock opened at $10.16 on Tuesday. Astria Therapeutics has a fifty-two week low of $4.97 and a fifty-two week high of $16.90. The firm has a market capitalization of $573.33 million, a price-to-earnings ratio of -4.86 and a beta of 0.67. The stock’s fifty day moving average is $10.92 and its two-hundred day moving average is $10.68.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently added to or reduced their stakes in ATXS. Quest Partners LLC increased its stake in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,112 shares during the last quarter. PDT Partners LLC purchased a new stake in Astria Therapeutics in the third quarter valued at approximately $140,000. SG Americas Securities LLC purchased a new stake in Astria Therapeutics in the third quarter valued at approximately $155,000. Hsbc Holdings PLC acquired a new position in Astria Therapeutics during the second quarter worth approximately $171,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics during the first quarter worth approximately $200,000. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.